EU’s AMR Transferable Exclusivity Voucher Plan 'Not Fit For Purpose'
Executive Summary
A European public health NGO has disputed the suggestion that a transferable exclusivity extension is the answer to the lack of innovative antimicrobial drugs in company pipelines.
You may also be interested in...
Transferable Exclusivity Extension Vouchers Are Viable In Europe, But Back Up Required
A new study shows that transferable exclusivity extension vouchers are the best way of incentivizing antibiotic development in Europe. However, investors caution that other strategies must also be considered.
Payer Wish List For EU Pharma Legislation – Is The European Commission Listening?
At a recent webinar payers and health technology appraisal bodies gave further details on what they want included and left out of the European Commission’s overhaul of the EU pharmaceutical legislation. However, speakers voiced some concerns about whether their demands will be met.
EU Health Emergency Response Authority Calls On Off-Patent Sector
The director-general of the European Commission’s recently-formed Health Emergency Response Authority addressed delegates at the off-patent association Medicines for Europe’s 2022 annual conference, noting that HERA was preparing a report for post-summer as it assessed its priorities.